Azitra, Inc. (AZTR)

NYSEAMERICAN: AZTR · Real-Time Price · USD
0.2979
+0.0139 (4.89%)
At close: May 8, 2025, 4:00 PM
0.2921
-0.0058 (-1.95%)
Pre-market: May 9, 2025, 4:02 AM EDT
4.89%
Market Cap 4.46M
Revenue (ttm) 7,500
Net Income (ttm) -8.97M
Shares Out 14.98M
EPS (ttm) -2.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 333,958
Open 0.2816
Previous Close 0.2840
Day's Range 0.2816 - 0.3021
52-Week Range 0.2330 - 12.0000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 20, 2025

About AZTR

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epider... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2023
Employees 12
Stock Exchange NYSEAMERICAN
Ticker Symbol AZTR
Full Company Profile

Financial Performance

In 2024, Azitra's revenue was $7,500, a decrease of -98.91% compared to the previous year's $686,000. Losses were -$8.97 million, -29.05% less than in 2023.

Financial Statements

News

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 /PRNews...

13 days ago - PRNewsWire

Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

BRANFORD, Conn. , April 24, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, to...

14 days ago - PRNewsWire

Azitra to Present at Microbiome Times Partnering Forum

BRANFORD, Conn. , March 12, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, to...

2 months ago - PRNewsWire

Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

BRANFORD, Conn. , Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

2 months ago - PRNewsWire

Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

BRANFORD, Conn. , Feb. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...

3 months ago - PRNewsWire

Azitra, Inc. to Present at the BIO CEO & Investor Conference

BRANFORD, Conn. , Feb. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...

3 months ago - PRNewsWire

Azitra, Inc. to Present at The Microcap Conference

BRANFORD, Conn. , Jan. 27, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

3 months ago - PRNewsWire

Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

BRANFORD, Conn. , Jan. 15, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

4 months ago - PRNewsWire

Azitra Announces Proposed Public Offering of Common Stock

BRANFORD, Conn. , Jan. 14, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

4 months ago - PRNewsWire

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

6 months ago - PRNewsWire

Azitra to Present at BIO-Europe 2024

BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #bioeurope2024--Azitra will present a corporate presentation at BIO-Europe 2024 in Stockholm on Monday, November 4.

6 months ago - Business Wire

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #Maxim--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, ...

7 months ago - Business Wire

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

BRANFORD, Conn.--(BUSINESS WIRE)---- $AZTR #EADV2024--Azitra will be presenting a late-breaking presentation at #EADVCongress 2024 on Thursday, September 26.

8 months ago - Business Wire

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...

8 months ago - Business Wire

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Compa...

8 months ago - Business Wire

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluatin...

9 months ago - Business Wire

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...

9 months ago - Business Wire

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evalu...

9 months ago - Business Wire

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...

9 months ago - Business Wire

CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering

BRANFORD, Conn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: AZITRA, INC. ANNOUNCES CLOSING OF $10.0 MILLION ...

10 months ago - Business Wire

You.com Announces Strategic Collaboration With Moesif to Drive Productivity and Power Usage-Based Billing

PALO ALTO, Calif.--(BUSINESS WIRE)--You.com, the AI-powered productivity engine, today announced a new strategic collaboration with Moesif, a leading provider of monetization and usage-based billing f...

Other symbols: HAL
10 months ago - Business Wire

Wingspire Equipment Finance's $12 Million Funding Initiative to Propel Tier 1 Aerospace Manufacturer Capabilities

TUSTIN, Calif.--(BUSINESS WIRE)--Wingspire Equipment Finance is proud to announce a $12,000,000 equipment financing to a leading aerospace manufacturing company. The Tier 1 aerospace manufacturer is k...

Other symbols: HAL
10 months ago - Business Wire

Azitra, Inc. Announces Pricing of $10.0 Million Public Offering

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...

10 months ago - Business Wire

Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...

10 months ago - Business Wire

Azitra, Inc. Announces Reverse Stock Split

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...

11 months ago - Business Wire